International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery

SINGAPORE, September 28 /PRNewswire/ --

NeuroAid(TM) is the first natural compound to be studied in a large
clinical trial focused on stroke recovery starting in the acute stage.

The CHIMES study is a multi-center double-blind placebo-controlled
randomized trial to evaluate the efficacy of NeuroAid(TM) in reducing
neurological deficit and improving independence in patients in
rehabilitation, with treatment starting within 48 hours of a stroke. Already
studied in a rehabilitation setting with initiation of treatment within 14
days of stroke incidence, NeuroAid(TM) will now be evaluated when
administered in the acute stage, with periodic assessments for three months.
The study will begin enrollment of 1,100 patients in early October 2007 at
several hospitals in Singapore, followed by hospitals in the Philippines and
in Thailand.

The study will be conducted by CHIMES Society, an international
partnership of Key Opinion Leaders in stroke whose objective is to establish
new stroke treatments.

Professor Marie-Germaine Bousser, Head of the Neurology Department at
Lariboisiere Hospital in Paris, France and member of the Council of the
American Stroke Association, commented, "Recent drug trials in the acute
treatment of stroke have unfortunately all been negative. It is thus very
exciting to take a completely new approach and to scientifically test in
different populations a compound that has long been used in Traditional
Chinese Medicine."

David Picard, CEO of Moleac, the Singapore/Biopolis-based global
biopharmaceutical company that develops and markets NeuroAid(TM) outside of
China, said: "We are delighted at the interest NeuroAid(TM) has generated in
the medical community worldwide. Over 200,000 patients in China alone are
using NeuroAid(TM) every year, and patient feedback from other countries is
very positive. Our next milestone is to generate clinical data in the acute
phase, with studies that meet the standards of European and U.S. regulatory
authorities." "Our ultimate goal is to see NeuroAid(TM) included in key
treatment guidelines for stroke victims, making its benefits available to all
patients who need it," David added.

NeuroAid(TM)'s efficacy and safety was tested in a multi-centre double
blind randomized clinical trial conducted on 605 patients in China in
1999-2000. Patients taking NeuroAid(TM) were shown to be 2.11 times more
likely to reach functional independence and 1.7 times more likely to reduce
their neurological deficit by at least 55% than patients who did not take the
product. It helped improve stroke patients' ability to recover even when
treatment was started several weeks after the onset of stroke.

About NeuroAid(TM)

NeuroAid(TM) is a Traditional Chinese Medicine that provides faster and
more extensive recovery of motor and cognitive functions in stroke patients
during rehabilitation. It is a combination of fourteen all-natural
ingredients from the Chinese medicinal pharmacopoeia, formulated according to
international Good Manufacturing Practice (GMP) standards. It is marketed
internationally by Moleac, the biopharmaceutical company that identified the
product in China as the first medicine to help improve stroke recovery.
NeuroAid(TM) is currently marketed in Singapore as a Chinese proprietary
medicine, and in other countries in the region as a dietary supplement. It is
also sold internationally by Moleac via the website http://www.neuroaid.com .
With the CHIMES study, NeuroAid(TM) is the first traditional medicine in the
world to be studied in a large scale evidence-based clinical trial.

About Moleac

Moleac is a biopharmaceutical company based in Biopolis, a world-class
purpose built complex for biomedical sciences research in Singapore 
( http://www.biopolis.com ). Moleac identifies promising medicines
discovered in China and develops them into Western mainstream medicine.
Moleac also develops innovative technologies and medical products in-licensed
from Europe and the US, and markets them in Asia. Focusing on patients'
greatest needs and specific unmet medical needs, Moleac drives research,
development and registration for a pipeline of drugs and devices in various
stages of development. Moleac seeks partners to bring these products to
market and will continue to evaluate new opportunities.

Moleac's first product derived from Traditional Chinese Medicine,
NeuroAid(TM), has gained market approval in two countries in 2006 and will be
available to stroke sufferers around the world in 2007-2008. Moleac also
plans the launch of a smoking cessation therapy that will reach key global
markets in 2007.

About CHIMES Society

CHIMES Society is an international partnership of Key Opinion Leaders in
stroke whose objective is to establish new stroke treatments. Members include
physicians, academics, and clinicians, several of which are renowned
neurologists from Europe and Asia. The team received a grant from the
National Medical Research Council (NMRC) of Singapore to undertake the study
over a period of two years. For further information visit
http://www.chimes-society.org .

DISCLOSURE NOTICE: The information contained in this release is as of
September 24, 2007. Moleac assumes no obligation to update any
forward-looking statements contained in this release as the result of new
information or future events or developments. This release contains
forward-looking information about the potential benefits of NeuroAid(TM) that
involves substantial risks and uncertainties. Such risks and uncertainties
include, among other things, the uncertainties inherent in research and
development; decisions by regulatory authorities regarding whether and when
to approve any drug applications that may be filed as well as their decisions
regarding labeling and other matters that could affect its availability or
commercial potential; and competitive developments.

Contact:

    LEWIS
     Kristy Weller
     Tel: +65-6534-7250
     Mobile: +65-9069-3844
     Email: moleacsg@lewispr.com

    Web Site: http://www.chimes-society.org
              http://www.biopolis.com